Healthcare Venture Partners

Founded in 2019, Healthcare Venture Partners is a venture capital firm based in Charleston, South Carolina. It focuses on investing in healthcare, digital health, health technology, information technology, and life science sectors.

Jeffrey Lightcap

Founding Partner and Senior Managing Director

Michael Mashaal MD

Founding Partner and Senior Managing Director

3 past transactions

MyOme

Series B in 2022
MyOme develops a genetic testing technology that provides comprehensive health insights through whole genome sequencing. Its platform offers detailed reports on disease risk and medication response, accompanied by independent physician reviews and genetic counseling. The company ensures ongoing updates using advanced technologies, empowering individuals to make informed health decisions while maintaining data privacy and security.

Paige

Series C in 2021
Paige is a company focused on computational pathology, developing an AI-powered platform that assists pathologists in diagnosing cancer and guiding treatment decisions. The platform integrates deep learning models, including convolutional and recurrent neural networks and generative methods, to enable rapid diagnostic stratification and cancer detection, with emphasis on breast and prostate cancers. Designed to improve diagnostic confidence and workflow efficiency, Paige's lightweight solution aims to minimize IT burden while ensuring patient safety and data privacy. Paige holds a FDA Breakthrough designation for computational pathology products, highlighting its role in advancing pathology through automated analysis of tissue slides. The company targets clinical researchers and pathology teams with tools that deliver insights to support precise diagnoses and better patient outcomes.

Paige

Series B in 2019
Paige is a company focused on computational pathology, developing an AI-powered platform that assists pathologists in diagnosing cancer and guiding treatment decisions. The platform integrates deep learning models, including convolutional and recurrent neural networks and generative methods, to enable rapid diagnostic stratification and cancer detection, with emphasis on breast and prostate cancers. Designed to improve diagnostic confidence and workflow efficiency, Paige's lightweight solution aims to minimize IT burden while ensuring patient safety and data privacy. Paige holds a FDA Breakthrough designation for computational pathology products, highlighting its role in advancing pathology through automated analysis of tissue slides. The company targets clinical researchers and pathology teams with tools that deliver insights to support precise diagnoses and better patient outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.